Isomorphic Labs, an Alphabet-backed drug discovery startup spun out of Google DeepMind, is preparing to initiate its first human clinical trials for AI-designed medicines later this year. The company, which has received $600 million in funding and formed partnerships with pharmaceutical giants Novartis and Eli Lilly, aims to revolutionize drug development by significantly accelerating the lab-to-patient cycle and reducing costs by up to 90%. Leveraging AlphaFold's breakthrough in protein folding to predict precise 3D structures, Isomorphic Labs is focusing initially on AI-designed cancer treatments. Colin Murdoch, president of Isomorphic Labs and chief business officer at Google DeepMind, confirmed the company is "getting very close" to starting these trials. The initiative represents a shift from traditional trial-and-error drug discovery to algorithm-driven design, with ambitions to eventually cure all diseases using AI.